Want to see SCNX full AI Analyst Report?
SCNX Stock Chart & Stats
$0.38
-$0.13(-2.47%)
At close: 4:00 PM EST
$0.38
-$0.13(-2.47%)
Day’s Range― - ―
52-Week Range$3.23 - $65.00
Previous CloseN/A
Volume1.53K
Average Volume (3M)285.92K
Market Cap
$6.42M
Enterprise Value$16.37M
Total Cash (Recent Filing)$8.19M
Total Debt (Recent Filing)$10.69M
Price to Earnings (P/E)―
Beta2.70
Next Earnings
Nov 12, 2026EPS Estimate
-1.5Next Dividend Ex-DateN/A
Dividend Yield24.3%
Share Statistics
EPS (TTM)-46.25
Shares Outstanding1,642,565
10 Day Avg. Volume734,969
30 Day Avg. Volume285,917
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.12
Price to Sales (P/S)181.35
P/FCF Ratio-5.85
Enterprise Value/Market Cap2.55
Enterprise Value/Revenue19.93
Enterprise Value/Gross Profit64.84
Enterprise Value/Ebitda-0.46
Forecast
1Y Price Target
$37.50Price Target Upside9768.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-7.5
Revenue Forecast (FY)$5.12M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthTTM revenue growth of 71.94% indicates the company is expanding its commercial product base or sales reach. If this pace translates into repeat demand, it can improve operating leverage and create a larger platform for future pharmaceutical commercialization.
Positive Gross MarginA positive TTM gross margin of about 30.7% shows that products generate gross profit before operating expenses. That provides a foundation for eventual scale benefits, although the margin’s historical volatility means this advantage is not yet consistently durable.
Moderate Current LeverageCurrent leverage appears moderate, with debt-to-equity near 0.17 and equity substantially exceeding debt in the latest period. This gives the company more balance-sheet capacity than a highly levered peer to fund commercialization or manage operating volatility.
Bears Say
Severe Persistent LossesDeeply negative net, EBIT, and EBITDA margins show that revenue growth is not yet translating into a viable earnings model. Persistent operating losses can limit internally funded investment, weaken financial resilience, and make sustainable profitability dependent on major cost improvement.
Heavy Cash BurnOperating and free cash flow of roughly negative $6.1B indicates that the business is consuming substantial cash rather than funding itself. Continued burn raises the likelihood of ongoing financing needs and can constrain product development, launches, and other strategic investment.
Balance-Sheet InstabilityAlthough current leverage is moderate, the historically unstable capital structure reduces confidence that today’s balance-sheet profile will persist. Slightly negative TTM ROE also shows the equity base is not yet producing sustainable returns, weakening long-term capital efficiency.
Scienture Holdings News
SCNX FAQ
What was Scienture Holdings’s price range in the past 12 months?
Scienture Holdings lowest stock price was $3.23 and its highest was $65.00 in the past 12 months.
What is Scienture Holdings’s market cap?
Scienture Holdings’s market cap is $6.42M.
When is Scienture Holdings’s upcoming earnings report date?
Scienture Holdings’s upcoming earnings report date is Nov 12, 2026 which is in 29 days.
How were Scienture Holdings’s earnings last quarter?
Scienture Holdings released its earnings results on Aug 14, 2026. The company reported -$1.75 earnings per share for the quarter, beating the consensus estimate of -$2.25 by $0.5.
Is Scienture Holdings overvalued?
According to Wall Street analysts Scienture Holdings’s price is currently Undervalued.
Does Scienture Holdings pay dividends?
Scienture Holdings pays a Notavailable dividend of $37.5 which represents an annual dividend yield of 24.3%. See more information on Scienture Holdings dividends here
What is Scienture Holdings’s EPS estimate?
Scienture Holdings’s EPS estimate is -1.5.
How many shares outstanding does Scienture Holdings have?
Scienture Holdings has 1,642,565 shares outstanding.
What happened to Scienture Holdings’s price movement after its last earnings report?
Scienture Holdings reported an EPS of -$1.75 in its last earnings report, beating expectations of -$2.25. Following the earnings report the stock price went down -1.299%.
Which hedge fund is a major shareholder of Scienture Holdings?
Currently, no hedge funds are holding shares in SCNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Scienture Holdings
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.
SCNX Stock 12 Month Forecast
Average Price Target
$37.50
▲(9768.42% Upside)
Technical Analysis
Ownership Overview
16.65% Insiders
1.69% Mutual Funds
― Other Institutional Investors
80.42% Public Companies and
Individual Investors